IBRX - Company ID 0001326110
The table below shows ImmunityBio, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$304.94M | -$391.24M | -$366.76M | -$337.51M | -$274.42M | -$171.72M |
| Capital expenditure | $3.85M | $6.89M | $30.58M | $78.16M | $33.56M | $1.67M |
| Investing cash flow | -$149.80M | -$12.25M | -$30.47M | $27.30M | -$84.89M | -$19.81M |
| Dividends paid | - | - | - | - |
ImmunityBio, Inc. reported operating cash flow of -$304.94M for fiscal year 2025. That is up 22.1% from -$391.24M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$38.59M (FY 2016) to -$304.94M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | $0.00 | $0.00 |
| Financing cash flow | $400.24M | $281.63M | $558.34M | $233.61M | $505.44M | $150.68M |